2nd Quarter - Report

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$2,290,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 974 CREATES Act of 2017 S. 124 Preserve Access to Affordable Generics Act Issues related to drug patents and exclusivities (no bill)

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Commerce, Dept of (DOC); Treasury, Dept of; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Executive Office of the President (EOP)

Bills named: S. 974 (115th), S. 124 (115th)

Taxation/Internal Revenue Code TAX

International tax issues, including: H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 Puerto Rico Tax Incentives

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
NANCY ELLEN MCCARTHY —

Contacted: Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Treasury, Dept of; SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1 (115th)

Health Issues HCR

Biosimilars, no specific bill Prescription drug value issues, no specific bill S. 469 Affordable and Safe Prescription Drug Importation Act H.R. 1245 Affordable and Safe Prescription Drug Importation Act S.Con.Res.3 A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018-2026 (importation, non-interference) 340B Protecting Access for the Underserved and Safety-Net Entities (340B PAUSE Act). S. 2042 Reducing Drug Waste Act of 2017 H.R. 6142 Reducing Drug Wastage Act of 2018 FDA issues, no specific bill S.3158 Labor, Health and Human Services Appropriations Act (Senate Report 115-289)

Contacted: Office of Management & Budget (OMB); SENATE; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: S.Con.Res. 3 (115th), S. 3158 (115th), H.R. 6142 (115th), S. 2042 (115th), S. 469 (115th), H.R. 1245 (115th)

Medicare/Medicaid MMM

Medicare Part B (Average Sales Price) Medicare Part D issues Coding and reimbursement for oncology drugs/biologics/biosimilars 340B Protecting Access for the Underserved and Safety-Net Entities S 2312 "Helping Ensure Low-Income Patients have Access to Care and Treatment" (HELP Act) S 2453 "Ensuring the Value of the 340B Program Act of 2018" H.R. 5598 "340B Optimization Act" Senate Report 115-289 to accompany S.3158 Appropriations bill for the Department of Labor, Health and Human Services, and Education, and related agencies for the fiscal year 2019 H.R. 6142 Reducing Drug Waste Act

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: Health & Human Services, Dept of (HHS); Treasury, Dept of; SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Office of Management & Budget (OMB)

Bills named: H.R. 5598 (115th), S. 3158 (115th), H.R. 6142 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.